InVivoSIM anti-human TROP-2 (Sacituzumab Biosimilar)

About InVivoSIM anti-human TROP-2 (Sacituzumab Biosimilar)

This biosimilar antibody uses the same variable regions as the therapeutic antibody Sacituzumab, making it ideal for research use. Sacituzumab is a fully humanized IgG1κ monoclonal antibody that reacts with human trophoblastic cell surface antigen 2 (TROP-2), an antigen linked to cancer. TROP-2 is a cell surface receptor that spans the cellular membrane with an extracellular, transmembrane, and intracellular domain, along with a cytoplasmic tail essential for signaling. The ligands of TROP-2 include claudin-1, claudin-7, cyclin D1, and potentially IGF-1. TROP-2 upregulates EpCAM-triggered cell signaling and requires RIP to regulate efficient growth and division of cancer cells. Several proteins, including RIP, TACE, γ-secretase, Presenilin 1 (PS-1) and PS-2, facilitate TROP-2’s cleavage within the transmembrane domain, and this cleavage produces TROP-2 extracellular domain (ECD) and intracellular domain (ICD) fragments. TROP-2 is considered a cellular marker of trophoblastic stem cells, and this glycoprotein is known to transduce calcium signals. Normal epithelial cells express TROP-2 at a low level, while many tumors (such as glioblastoma, pancreatic carcinoma, and all breast cancer subtypes, especially triple-negative breast cancer) express it at a high level. The critical role of TROP-2 in multiple signaling pathways often links to the proliferation, invasion, and metastasis of tumors. The tumor cell-specific expression of TROP-2 makes it an ideal target for cancer immunotherapy. Several recent studies have used Sacituzumab-based antibody-drug conjugates (ADC), namely Sacituzumab Govitecan (IMMU-132) that contains Sacituzumab conjugated to SN-38 (the active metabolite of irinotecan), utilizing a pH hydrolysable linker CL2A for facilitating SN-38 release to the cancer cells in in vitro and in vivo preclinical studies.